

ABBOTT LABORATORIES  
Form 8-K  
December 04, 2015

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D. C. 20549

---

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the**  
**Securities Exchange Act of 1934**

**November 30, 2015**

Date of Report (Date of earliest event reported)

**ABBOTT LABORATORIES**

(Exact name of registrant as specified in charter)

---

**Illinois**  
(State or other Jurisdiction  
of Incorporation)

**1-2189**  
(Commission File Number)

**36-0698440**  
(IRS Employer  
Identification No.)

---

**100 Abbott Park Road**

Edgar Filing: ABBOTT LABORATORIES - Form 8-K

Abbott Park, Illinois 60064-6400

(Address of principal executive offices)(Zip Code)

Registrant's telephone number, including area code: **(224) 667-6100**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 5.04**

**Temporary Suspension of Trading Under Registrant's Employee Benefit Plans**

On November 30, 2015, Abbott Laboratories ( Abbott ) received a notice from the plan administrator of the Abbott Laboratories Stock Retirement Plan ( U.S. Plan ) and the Abbott Laboratories Stock Retirement Plan (Puerto Rico) ( P.R. Plan ; collectively, the Plans ) pursuant to Section 101(i)(2)(E) of the Employee Retirement Income Security Act of 1974 regarding a blackout period (the Blackout Period ) under the Plans. The Blackout Period is required because the Plans are making certain administrative changes, including changing the recordkeeper, changing the trustee of the U.S. Plan, and changing the custodian of the P.R. Plan.

During the Blackout Period, Plan participants will be unable to engage in transactions involving the assets held in their Plan accounts, including changing contribution rates, directing or diversifying investments (including investments in Abbott common shares), or obtaining a Plan loan, withdrawal, or distribution.

As described more fully in the Notice, the Blackout Period is expected to begin on January 7, 2016 at 2 p.m. CST and expected to end during the week of January 24, 2016. During the Blackout Period and for two years after the ending date of the Blackout Period, a security holder or other interested person may obtain, without charge, the actual beginning and ending dates of the Blackout Period, by submitting a request to Abbott Laboratories, 100 Abbott Park Road, Abbott Park, Illinois 60064, Attn: Divisional Vice President, Compensation and Benefits; (224) 667-6100.

On December 2, 2015, the Company sent an appropriate notice to its directors and executive officers (the Notice ) informing them of the Blackout Period and the restrictions on trading in Abbott common stock (including with respect to derivatives) that apply to them during the Blackout Period, pursuant to Section 306 of the Sarbanes-Oxley Act of 2002 and Rule 104 of Regulation BTR. A copy of the Notice is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference.

**Item 9.01 Financial Statements and Exhibits**

**Exhibit No.**

**Exhibit**

99.1 Notice provided to directors and executive officers of Abbott Laboratories on December 2, 2015.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**ABBOTT LABORATORIES**

Date: December 4, 2015

By:

*/s/ Brian B. Yoor*  
Brian B. Yoor  
Senior Vice President, Finance  
and Chief Financial Officer

**EXHIBIT INDEX**

<b>Exhibit No.</b>	<b>Exhibit</b>
99.1	Notice provided to directors and executive officers of Abbott Laboratories on December 2, 2015.